Medicamen Biotech Ltd

MEDICAMEQ
Health CarePharmaceuticals
SmallcapWith a market cap of ₹779 cr, stock is ranked 1,084
High RiskStock is 3.74x as volatile as Nifty
607.0531.10 (-4.87%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹779 cr, stock is ranked 1,084
High RiskStock is 3.74x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
52.29
PB RatioPB Ratio
5.87
Dividend YieldDiv. Yield
0.16%
Sector PESector PE
31.81
Sector PBSector PB
4.71
Sector Div YldSctr Div Yld
0.89%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

MEDICAMEN Biotech is engaged in manufacturing of pharmaceutical formulations.

Investor PresentationView older 

Dec 4, 2021

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

2019202020212022126.26127.44113.47117.1712.0313.2912.1314.91
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 1.24%

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Financial Result Updates 
Announced OnMay 25, 2022

Medicamen Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2022. | Download

Medicamen Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2022. | Download

Outcome of Board Meeting 
Announced OnMay 25, 2022

Medicamen Biotech Limited has informed the Exchange about Board Meeting held on 25-May-2022 to consider financial statements for the period ended March 2022 and Dividend | Download

Medicamen Biotech Limited has informed the Exchange about Board Meeting held on 25-May-2022 to consider financial statements for the period ended March 2022 and Dividend | Download

Cash Dividend 
Ex. DateSep 16, 2021

Final • Div/Share: ₹ 1

See all events